A recently released study in the journal Rheumatology titled “Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012,” shows higher mortality rates among people with systemic lupus erythematosus (SLE) compared to those without the disease. The study, led by senior researcher Dr. Weiya Zhang, M.D.,…
Lupus during pregnancy increases the likelihood of health complications for women and their babies, according to a study, “What to expect when expecting with SLE: A population-based study of maternal and fetal outcomes in SLE and pre-SLE,” published in the journal Arthritis Care and Research. Adverse pregnancy outcomes…
In a review titled “Immunoregulation of NKT Cells in Systemic Lupus Erythematosus,” published in the Journal of Immunology Research, researchers summarized the role of a specific class of immune cells – natural killer T (NKT) cells – highlighting their potential as a new therapeutic target for systemic lupus erythematosus (SLE).
Aurinia Pharmaceuticals, Inc., has announced its AURA-LV clinical study has completed enrollment and will be treating a total of 265 lupus patients, surpassing its target of 258 patients. AURA-LV (Aurinia Urine protein Reduction in Active Lupus nephritis) is a Phase 2b is randomized, controlled, double-blind clinical trial to compare the efficacy of voclosporin…
An international team of researchers has identified 10 new genes associated with the development of systemic lupus erythematosus (SLE) that might constitute potential therapeutic targets for the disease. The research paper, “High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry,” was published in Nature Genetics.
A recent study revealed that mitochondria induce inflammation in lupus through the release of reactive oxygen species into neutrophil extracellular traps (NETs). The research, “Neutrophil extracellular traps enriched in oxidized mitochondria DNA are interferogenic and contribute to lupus-like disease,” offers hope for new lupus treatments. Neutrophils are white blood cells…
A study from the Scripps Research Institute shows that harmful autoimmune responses, as seen in diseases like systemic lupus erythematosus (SLE), can be controlled without compromising the normal activity of the immune system when fighting viruses and bacteria. The key, according…
Neovacs and Stellar Biotechnologies have collaborated to form a new biotech company called Neostell SAS. Neovacs will own 70 percent of the new company and Stellar Biotechnologies will own the remaining 30 percent. Neovacs is a European leader in immunotherapies developed to treat autoimmune diseases. It’s lead active immunotherapy candidate is IFNα-Kinoid,…
The role of the female hormone estrogen in two predominantly female autoimmune diseases — multiple sclerosis and systemic lupus erythematosus — is the focus of a recent review study, “The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases.” The…
Systemic lupus erythematosus (SLE) patients may be at a higher risk of seizures if they have a history of psychosis, neuropathy, proteinuria, or are currently using corticosteroids — among other factors — according to a study recently published in the Journal of Rheumatology, titled “Predictors of Incident Seizure in Systemic…